Ipamorelin: The Complete Research Guide (2026)

Growth hormone output drops by approximately 14% per decade after age 30, and the research community has been searching for selective, well-tolerated compounds to study this decline and its consequences. Ipamorelin has become one of the most studied growth hormone-releasing peptides (GHRPs) in that search. Unlike earlier GHRPs that triggered broad hormonal cascades - raising cortisol, prolactin, and ACTH alongside GH - Ipamorelin achieves selective GH stimulation through a distinctly clean pharmacological profile. Since its first characterization in 1998 (Raun et al., Eur J Endocrinol), it has accumulated a substantial research record in both animal models and early human studies.

This guide covers everything researchers need to know about Ipamorelin in 2026: its molecular mechanism, what the published literature shows, how it compares to other GH secretagogues, and how it performs in combination with CJC-1295 - the stack that has driven some of the most cited recent research.

Key Takeaways

• Ipamorelin is a selective GHRP (growth hormone-releasing peptide) that stimulates pulsatile GH release through the ghrelin receptor (GHSR-1a) without significantly raising cortisol, prolactin, or ACTH
• It is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) with a short half-life of approximately 2 hours, making it suitable for studies requiring precise dosing windows
• Research consistently shows GH pulses 2-10x above baseline with minimal off-target hormonal activity
• The CJC-1295 + Ipamorelin combination is the most studied GHRH/GHRP stack, with synergistic effects on GH amplitude and IGF-1 elevation
• Ipamorelin research spans body composition, bone density, GI motility, and aging models

Table of Contents

1. What is Ipamorelin?
2. Mechanism of Action
3. Published Research and Findings
4. Ipamorelin vs Other GHRPs: Comparison
5. CJC-1295 + Ipamorelin Stack Research
6. Research Protocols and Dosing - see also our step-by-step Ipamorelin how-to guide
7. Ipamorelin for Specific Research Models
8. Storage, Reconstitution, and Handling
9. Safety Profile
10. Frequently Asked Questions

What is Ipamorelin? {#what-is-ipamorelin}

The problem: Most growth hormone-releasing peptides developed in the 1990s activated GH secretion but also triggered significant elevations in cortisol, prolactin, and adrenocorticotropic hormone (ACTH). This hormonal noise complicated interpretation of research findings and limited the compounds' utility for long-term animal models.

The solution: Ipamorelin was designed specifically for selectivity. Developed by Novo Nordisk and first described by Raun and colleagues in 1998, it is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 (Raun K. et al., 1998, European Journal of Endocrinology, doi: 10.1530/eje.0.1390552). The non-standard amino acids - particularly the incorporation of D-2-naphthylalanine and alpha-aminoisobutyric acid - confer both receptor selectivity and resistance to enzymatic degradation.

Ipamorelin belongs to the growth hormone secretagogue (GHS) class and acts as an agonist at the ghrelin receptor (GHS-R1a). It is currently available as a research chemical and is not approved for human therapeutic use by the FDA or EMA, making it relevant exclusively for preclinical and research contexts.

Key properties at a glance:

• Molecular formula: C38H49N9O5
• Molecular weight: 711.86 g/mol
• Half-life: approximately 2 hours (IV/SC)
• Receptor target: GHS-R1a (ghrelin receptor)
• Selectivity: GH only, minimal cortisol/ACTH/prolactin elevation
• Administration routes studied: subcutaneous, intravenous

Mechanism of Action {#mechanism-of-action}

The problem: Understanding how Ipamorelin produces GH pulses without systemic hormonal disruption requires a detailed look at the pituitary signaling cascade it engages.

The solution - the GHS-R1a pathway: Ipamorelin binds to the GHS-R1a receptor, a G protein-coupled receptor (GPCR) expressed on somatotroph cells in the anterior pituitary. Upon binding, it activates the Gq/11 signaling pathway, triggering phospholipase C (PLC) activity, IP3-mediated calcium release from the endoplasmic reticulum, and ultimately exocytosis of GH-containing secretory granules (Svensson J. et al., 2000, Journal of Endocrinology, doi: 10.1677/joe.0.1640519).

What makes it selective:

The key distinction lies in what Ipamorelin does NOT activate. Earlier GHRPs like GHRP-6 and GHRP-2 also engage additional pathways that elevate cortisol and ACTH - Ipamorelin's unique binding geometry at GHS-R1a appears to achieve full GH efficacy without triggering these off-target cascades. This was confirmed in comparative studies by Johansen et al. (1999, Growth Hormone & IGF Research, doi: 10.1054/ghir.1999.9993) showing Ipamorelin produced equivalent GH pulses to GHRP-6 with statistically significant differences in cortisol elevation.

Synergy with GHRH:

Ipamorelin's effect is amplified when combined with growth hormone-releasing hormone (GHRH) or its analogs. While Ipamorelin acts on pituitary somatotrophs directly through GHS-R1a, GHRH analogs like CJC-1295 act through the GHRH receptor (GHRHR) via the Gs/cAMP/PKA pathway. These two pathways are complementary - activating both simultaneously produces GH pulses substantially larger than either compound alone, which forms the mechanistic rationale for the CJC-1295/Ipamorelin stack.

Published Research and Findings {#published-research-and-findings}

Ipamorelin's research record spans roughly 25 years and covers multiple organ systems. Here are the most significant areas:

Growth Hormone and IGF-1 Elevation

The foundational finding in Ipamorelin research is reliable, dose-dependent GH stimulation. Raun et al. (1998) demonstrated that a single subcutaneous injection in rats produced GH pulses 2.2-fold above controls at 1 nmol/kg and 10-fold above controls at higher doses. Importantly, serum cortisol and ACTH remained statistically indistinguishable from controls across all doses tested - a landmark result that established Ipamorelin as the first selective GHRP.

Downstream, GH stimulation drives IGF-1 synthesis in the liver. Sustained IGF-1 elevation has been associated in research models with increased protein synthesis, reduced fat mass, and improvements in markers of connective tissue integrity. These findings have made Ipamorelin a standard compound in body composition research.

Bone Density Research

A significant branch of Ipamorelin research involves bone formation. Svensson et al. (2000) conducted an 8-week study in adult female rats and demonstrated statistically significant increases in bone mineral content and cortical bone width in Ipamorelin-treated animals compared to controls. The researchers proposed that this effect was mediated through both direct GH/IGF-1 axis stimulation and possible direct effects of GHS-R1a activation on osteoblast activity. This positions Ipamorelin as a relevant tool in osteoporosis and bone aging research.

GI Motility Research

Ipamorelin has also been studied in the context of gastrointestinal motility. GHS-R1a receptors are expressed not just in the pituitary but throughout the enteric nervous system, and ghrelin receptor agonists have documented effects on gastric emptying and intestinal motility. Research in animal models of post-operative ileus (reduced gut motility following abdominal surgery) has shown that Ipamorelin administration accelerated return of normal GI function compared to controls - a finding of potential relevance for post-surgical recovery research (Andersen B.N. et al., 2001, Regulatory Peptides, doi: 10.1016/S0167-0115(01)00158-4).

Research in Aging Models

Growth hormone axis decline is a central feature of biological aging - somatopause, the age-related decline in GH/IGF-1 signaling, begins in the third decade of life and accelerates thereafter. Ipamorelin has been used extensively in aging animal models to study whether restoration of pulsatile GH release through GHRP administration can attenuate age-associated changes in body composition, metabolic function, and physical capacity. While results vary by model and endpoint, these studies have consistently demonstrated that Ipamorelin maintains efficacy in older animals, making it useful for longitudinal aging research.

For broader context on the current peptide research landscape, see the Most Studied Research Peptides in 2026 overview.

Ipamorelin vs Other GHRPs: Comparison {#ipamorelin-vs-other-ghrps}

Ipamorelin sits in a class of compounds alongside GHRP-2, GHRP-6, and Hexarelin. Understanding how they differ helps researchers select the right tool for specific protocols.

Key takeaway: Ipamorelin is the most selective injectable GHRP for isolating the effects of GH stimulation without hormonal confounders. MK-677 offers the convenience of oral administration and a longer half-life, but produces moderate prolactin elevation and is a non-peptide compound with a different pharmacological profile.

For research requiring clean GH pulses with minimal endocrine noise, Ipamorelin is the standard reference compound in the GHRP class.

Explore Ipamorelin for Research Vantage Peptide supplies research-grade Ipamorelin with independent third-party COA verification, HPLC purity testing, and mass spectrometry identity confirmation. View Ipamorelin | Full Peptide Catalog

CJC-1295 + Ipamorelin Stack Research {#cjc-1295-ipamorelin-stack}

The problem: Ipamorelin alone produces strong GH pulses, but its short half-life (approximately 2 hours) means GH elevation is transient. Researchers seeking sustained GH/IGF-1 elevation needed a way to extend the GH release window. For a full comparison of how CJC-1295 stacks up against Ipamorelin, GHRP-6, Sermorelin, and AOD-9604, see the CJC-1295 vs Other GH Secretagogues guide.

The solution: Combining Ipamorelin with CJC-1295, a long-acting GHRH analog with a half-life of 7-10 days (with DAC) or 30-60 minutes (without DAC), creates a two-pronged attack on GH secretion. CJC-1295 primes and prepares somatotroph cells for release through the GHRHR/cAMP pathway, while Ipamorelin triggers the acute pulse through GHS-R1a/Gq signaling.

What the research shows:

The synergistic effect of combining a GHRH analog with a GHRP is well-established. Studies using GHRH + GHRP-6 combinations demonstrated GH pulses 3-13 times larger than either compound alone, with the effect attributed to convergent signaling on somatotroph cells. Research with the specific CJC-1295/Ipamorelin combination has confirmed similar synergy, with IGF-1 elevations of 40-60% above baseline in animal models treated with the combination compared to 15-25% with either compound alone.

Research protocol considerations for the stack:

• CJC-1295 (no DAC) is typically administered at the same time as Ipamorelin to synchronize GHRH priming with GHRP pulse induction
• CJC-1295 (with DAC) can be dosed less frequently due to its long half-life, with Ipamorelin added for acute GH pulse amplification
• The combination is most commonly studied for body composition endpoints including fat mass reduction, lean mass accretion, and bone mineral density

See our dedicated CJC-1295 Complete Guide for full mechanistic details on the GHRH analog side of this stack.

Research Protocols and Dosing {#research-protocols-and-dosing}

The following describes dosing ranges observed in published research and preclinical studies. This information is for research purposes only and does not constitute medical or clinical guidance.

How to Set Up an Ipamorelin Research Protocol

1. Reconstitute the peptide using bacteriostatic water or sterile saline. For preparation guidance, see the Peptide Reconstitution Guide.

2. Verify purity documentation - confirm third-party COA shows HPLC purity average 99.7% and mass spectrometry confirmation of molecular weight. See the How to Read a Peptide COA Guide for a full walkthrough.

3. Calculate dose per body weight for animal studies. Published research has used ranges of 0.1-10 nmol/kg (subcutaneous) in rodent models. Human equivalent doses in early phase research have typically ranged from 200-300 mcg per administration.

4. Choose administration timing based on research endpoint. GH secretion follows a natural circadian rhythm with pulses occurring primarily during sleep and fasting states. Administration timing relative to feeding and activity cycles significantly affects measured GH response.

5. Plan measurement windows - peak GH response typically occurs 30-60 minutes post-injection with subcutaneous dosing. IGF-1 elevation is measurable at 8-24 hours and reflects cumulative GH activity.

6. Store properly before and after reconstitution - see the Peptide Storage Guide for temperature and light stability requirements specific to pentapeptides.

Typical Research Frequencies

• Short-term GH pulse studies: single injection protocols measuring 0-240 minute hormone profiles
• Chronic body composition studies: daily administration for 4-12 weeks with endpoint measurements at baseline, mid-study, and termination
• Bone density studies: 8-12 week protocols with DEXA measurements

Ipamorelin for Specific Research Models {#specific-research-models}

Aging and Somatopause Research

The age-related decline in GH/IGF-1 axis activity (somatopause) is one of the most active research areas for Ipamorelin. Researchers studying this area typically use aged rodent models (18-24 month mice or rats) and measure changes in:

• Serum GH and IGF-1 levels
• Body composition (fat mass vs lean mass ratio)
• Grip strength and locomotor activity
• Bone mineral density

For comparative context, MOTS-c is another peptide being studied in aging models, though through a different metabolic mechanism (mitochondrial signaling rather than the GH axis).

Post-Surgical Recovery Research

The GI motility applications of Ipamorelin have made it relevant for surgical recovery models. Post-operative ileus - a common complication following abdominal surgery in which normal intestinal peristalsis is delayed or absent - causes significant morbidity in clinical settings. Animal studies using Ipamorelin in surgical ileus models have shown accelerated return of bowel sounds, reduced time to first defecation, and decreased inflammatory markers in intestinal tissue.

Immune Function Research

GH has documented immunomodulatory effects, and there is emerging interest in whether GH secretagogues like Ipamorelin can influence immune parameters. This area overlaps with research on compounds like Thymosin Alpha-1 and GHK-Cu, which act through different mechanisms to modulate immune function and tissue repair.

Research-Grade Ipamorelin with Full Documentation All Vantage Peptide peptides are produced under GMP-aligned standards with independent purity testing. Every batch ships with HPLC analysis and mass spec identity confirmation. Shop Ipamorelin | View All Peptides

Storage, Reconstitution, and Handling {#storage-and-handling}

Ipamorelin is supplied as a lyophilized (freeze-dried) powder and requires proper storage and reconstitution for research validity.

Lyophilized storage: Store unreconstituted Ipamorelin at -20 degrees C to -80 degrees C in a sealed vial away from light. Under these conditions, lyophilized peptides retain potency for 24-36 months. Avoid repeated freeze-thaw cycles as these degrade peptide integrity.

Reconstitution: Use sterile bacteriostatic water (preferred for multi-use vials) or sterile saline. Add diluent slowly down the side of the vial - do not inject directly onto the powder cake or vortex vigorously, as mechanical agitation can disrupt peptide structure. Gently swirl until dissolved. For detailed step-by-step protocol see the Peptide Reconstitution Guide.

Reconstituted storage: Reconstituted Ipamorelin should be stored at 2-8 degrees C (standard refrigerator). Bacteriostatic water as diluent extends stability to approximately 4 weeks refrigerated; sterile saline without preservative should be used within 5-7 days.

Safety Profile {#safety-profile}

Ipamorelin's safety profile is among the most favorable in the GHRP class, and this is a key reason it remains a standard reference compound in GH secretagogue research.

Hormonal selectivity: As established in the original Raun et al. studies and confirmed in subsequent work, Ipamorelin does not significantly elevate cortisol, ACTH, prolactin, FSH, LH, or TSH at doses that produce robust GH stimulation. This clean hormonal profile makes it substantially easier to interpret research results compared to less selective GHRPs.

No known receptor desensitization: Unlike some GHRPs, Ipamorelin has not shown significant GHS-R1a desensitization with chronic dosing in animal studies. Animals treated daily for 8+ weeks maintained GH responses similar to early treatment, suggesting the receptor does not become refractory.

GH-related effects: Any GH secretagogue carries the inherent risk profile of elevated GH, including potential for fluid retention, joint discomfort, and glucose metabolism effects in long-term studies. These should be monitored in extended research protocols.

Research classification: Ipamorelin is a research chemical and is not approved for human use. All handling must comply with applicable institutional and regulatory requirements.

Frequently Asked Questions {#faq}

What is Ipamorelin used for in research?

Ipamorelin is used to study the effects of selective growth hormone stimulation in animal models. Primary research applications include body composition studies, bone density research, GI motility investigations, and aging models. It is valued for its clean pharmacological profile - producing robust GH pulses without significantly elevating cortisol, prolactin, or ACTH.

How does Ipamorelin differ from GHRP-6?

Both Ipamorelin and GHRP-6 stimulate GH release through the GHS-R1a receptor, but their selectivity differs significantly. GHRP-6 produces notable cortisol and ACTH elevations alongside GH stimulation, complicating data interpretation. Ipamorelin achieves equivalent or greater GH stimulation with minimal off-target hormonal activity, making it the preferred compound for research isolating the GH axis.

Why is Ipamorelin often combined with CJC-1295 in research?

CJC-1295 and Ipamorelin act through different but complementary receptors on pituitary somatotroph cells. CJC-1295 activates the GHRH receptor (Gs/cAMP pathway), while Ipamorelin activates GHS-R1a (Gq/calcium pathway). When both pathways are activated simultaneously, the resulting GH pulse is synergistically larger than either compound alone - typically 3-10 times the response to either peptide individually. This combination is used when researchers need maximal, sustained GH/IGF-1 elevation.

What is the half-life of Ipamorelin?

Ipamorelin has a plasma half-life of approximately 2 hours following subcutaneous administration. Peak GH stimulation occurs around 30-60 minutes post-injection. This relatively short half-life means GH pulses are transient, which is useful for studies requiring acute GH stimulation. For sustained GH elevation research, Ipamorelin is often combined with a long-acting GHRH analog like CJC-1295 with DAC.

Is Ipamorelin studied for menopause-related research?

Ipamorelin is being investigated in female hormonal aging models, including those related to somatopause in post-reproductive subjects. The GH axis declines alongside estrogen in female aging models, and GH secretagogues have been studied for their potential to address changes in bone density, fat redistribution, and metabolic parameters associated with this decline. Research in this area remains ongoing and primarily preclinical.